200 related articles for article (PubMed ID: 37238250)
1. Liver Involvement in Patients with Systemic Sclerosis: Role of Transient Elastography in the Assessment of Hepatic Fibrosis and Steatosis.
Cuomo G; Iandoli C; Galiero R; Caturano A; Di Vico C; Perretta D; Adamo PV; Ferrara R; Rinaldi L; Romano C; Sasso FC
Diagnostics (Basel); 2023 May; 13(10):. PubMed ID: 37238250
[No Abstract] [Full Text] [Related]
2. The inverse effect of meal intake on controlled attenuation parameter and liver stiffness as assessed by transient elastography.
Ratchatasettakul K; Rattanasiri S; Promson K; Sringam P; Sobhonslidsuk A
BMC Gastroenterol; 2017 Apr; 17(1):50. PubMed ID: 28407734
[TBL] [Abstract][Full Text] [Related]
3. The Prevalence of Liver Steatosis and Fibrosis Assessed by Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter in Apparently Healthy Romanian Medical Students.
Nastasa R; Stanciu C; Zenovia S; Singeap AM; Cojocariu C; Sfarti C; Girleanu I; Chiriac S; Cuciureanu T; Huiban L; Muzica CM; Trifan A
Diagnostics (Basel); 2021 Dec; 11(12):. PubMed ID: 34943578
[TBL] [Abstract][Full Text] [Related]
4. Simultaneously Screening for Liver Steatosis and Fibrosis in Romanian Type 2 Diabetes Mellitus Patients Using Vibration-Controlled Transient Elastography with Controlled Attenuation Parameter.
Trifan A; Stratina E; Nastasa R; Rotaru A; Stafie R; Zenovia S; Huiban L; Sfarti C; Cojocariu C; Cuciureanu T; Muzica C; Chiriac S; Girleanu I; Singeap AM; Stanciu C
Diagnostics (Basel); 2022 Jul; 12(7):. PubMed ID: 35885657
[TBL] [Abstract][Full Text] [Related]
5. Vibration Controlled Transient Elastography in Screening for Silent Liver Diseases.
Said E; Abdel-Gawad M; Abdelsameea E; Elshemy EE; Abdeen N; Elbasiony M; Omran D; Elesnawy Y; Eid A; Lashen SA; Elbahr O; Naguib GG; Afify S; Bahbah EI; Alboraie M
Eur J Gastroenterol Hepatol; 2023 Oct; 35(10):1204-1210. PubMed ID: 37577784
[TBL] [Abstract][Full Text] [Related]
6. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients.
Shen F; Zheng RD; Mi YQ; Wang XY; Pan Q; Chen GY; Cao HX; Chen ML; Xu L; Chen JN; Cao Y; Zhang RN; Xu LM; Fan JG
World J Gastroenterol; 2014 Apr; 20(16):4702-11. PubMed ID: 24782622
[TBL] [Abstract][Full Text] [Related]
7. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
[TBL] [Abstract][Full Text] [Related]
8. Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study.
Demir M; Deyneli O; Yılmaz Y
Turk J Gastroenterol; 2019 Mar; 30(3):266-270. PubMed ID: 30411703
[TBL] [Abstract][Full Text] [Related]
9. Clinical Relevance of Liver Involvement in the Clinical Course of Systemic Sclerosis.
Lorena M; Bellan M; Lepore M; Sola D; Pedrazzoli R; Rigamonti C; De Benedittis C; Manfredi GF; Acquaviva A; Tonello S; Rizzi M; Minisini R; Pirisi M; Sainaghi PP
J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207242
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with controlled attenuation parameter (CAP).
Cardoso AC; Perez RM; de Figueiredo-Mendes C; Carvalho Leite N; Moraes-Coelho HS; Villela-Nogueira CA
J Viral Hepat; 2018 Nov; 25(11):1244-1250. PubMed ID: 29768686
[TBL] [Abstract][Full Text] [Related]
11. Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis.
Shen F; Mi YQ; Xu L; Liu YG; Wang XY; Pan Q; Zhang RN; Hu XQ; Xu LM; Fan JG
Aliment Pharmacol Ther; 2019 Jul; 50(1):93-102. PubMed ID: 31094016
[TBL] [Abstract][Full Text] [Related]
12. Ultrasound-Guided Attenuation Parameter (UGAP) for the quantification of liver steatosis using the Controlled Attenuation Parameter (CAP) as the reference method.
Bende F; Sporea I; Șirli R; Bâldea V; Lazăr A; Lupușoru R; Fofiu R; Popescu A
Med Ultrason; 2021 Feb; 23(1):7-14. PubMed ID: 33220028
[TBL] [Abstract][Full Text] [Related]
13. Ultrasound and FibroScan
Salmi A; di Filippo L; Ferrari C; Frara S; Giustina A
Endocrine; 2022 Nov; 78(2):262-269. PubMed ID: 35980569
[TBL] [Abstract][Full Text] [Related]
14. Therapy with Oral Directly Acting Agents in Hepatitis C Infection Is Associated with Reduction in Fibrosis and Increase in Hepatic Steatosis on Transient Elastography.
Rout G; Nayak B; Patel AH; Gunjan D; Singh V; Kedia S; Shalimar
J Clin Exp Hepatol; 2019; 9(2):207-214. PubMed ID: 31024203
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
[TBL] [Abstract][Full Text] [Related]
16. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Cao YT; Xiang LL; Qi F; Zhang YJ; Chen Y; Zhou XQ
EClinicalMedicine; 2022 Sep; 51():101547. PubMed ID: 35844772
[TBL] [Abstract][Full Text] [Related]
17. Controlled Attenuation Parameter for Assessment of Hepatic Steatosis in Indian Patients.
Rout G; Kedia S; Nayak B; Yadav R; Das P; Acharya SK; Gunjan D; Singh V; Mahanta M; Gupta S; Aggarwal S; Shalimar
J Clin Exp Hepatol; 2019; 9(1):13-21. PubMed ID: 30765934
[TBL] [Abstract][Full Text] [Related]
18. Body mass index-based controlled attenuation parameter cut-offs for assessment of hepatic steatosis in non-alcoholic fatty liver disease.
Shalimar ; Kumar R; Rout G; Kumar R; Yadav R; Das P; Aggarwal S; Gunjan D; Saraya A; Nayak B
Indian J Gastroenterol; 2020 Feb; 39(1):32-41. PubMed ID: 32185692
[TBL] [Abstract][Full Text] [Related]
19. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
Chan WK; Nik Mustapha NR; Mahadeva S
J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
[TBL] [Abstract][Full Text] [Related]
20. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population.
Chon YE; Jung KS; Kim SU; Park JY; Park YN; Kim DY; Ahn SH; Chon CY; Lee HW; Park Y; Han KH
Liver Int; 2014 Jan; 34(1):102-9. PubMed ID: 24028214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
